Display options
Cite
Brunner SM, Itzel T, Rubner C, et al. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget. 2017;8(41):71002-71011doi: 10.18632/oncotarget.20238.
Brunner, S. M., Itzel, T., Rubner, C., Kesselring, R., Griesshammer, E., Evert, M., Teufel, A., Schlitt, H. J., & Fichtner-Feigl, S. (2017). Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget, 8(41), 71002-71011. https://doi.org/10.18632/oncotarget.20238
Brunner, Stefan M, et al. "Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival." Oncotarget vol. 8,41 (2017): 71002-71011. doi: https://doi.org/10.18632/oncotarget.20238
Brunner SM, Itzel T, Rubner C, Kesselring R, Griesshammer E, Evert M, Teufel A, Schlitt HJ, Fichtner-Feigl S. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget. 2017 Aug 09;8(41):71002-71011. doi: 10.18632/oncotarget.20238. eCollection 2017 Sep 19. PMID: 29050338; PMCID: PMC5642613.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Aug 09;8(41):71002-71011. doi: 10.18632/oncotarget.20238. eCollection 2017 Sep 19.

Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival.

Oncotarget

Stefan M Brunner, Timo Itzel, Christoph Rubner, Rebecca Kesselring, Eva Griesshammer, Matthias Evert, Andreas Teufel, Hans J Schlitt, Stefan Fichtner-Feigl

Affiliations

  1. Department of Surgery, University Medical Center Regensburg, Regensburg, Germany.
  2. Institute of Pathology, University Medical Center Regensburg, Regensburg, Germany.
  3. Department of Internal Medicine I, University Medical Center Regensburg, Regensburg, Germany.
  4. Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany.

PMID: 29050338 PMCID: PMC5642613 DOI: 10.18632/oncotarget.20238

Abstract

BACKGROUND & AIMS: The immunological microenvironment of HCC influences patient outcome, however, the role of B cells remains unclear. This study investigated effects of local B-cell infiltration in HCC cohorts on patient survival and immunological and molecular tumor microenvironment.

RESULTS: Unsupervised gene expression analysis of full cancer transcriptomes (N=2158) revealed a highly co-regulated immunological cluster in HCC that mainly contained immunoglobulin fragments. More specifically, in an independent patient cohort (N=242) that compares HCC with non tumorous liver tissue high expression of these B-cell associated genes was associated with better patient outcome (P=0.0149). Conclusively, the immunohistochemical analysis of another independent cohort of resected HCCs (N=119) demonstrated that infiltration of HCCs by CD20

METHODS: Gene expression of 2 independent HCC tissue databases was compared using microarrays. Additionally, tissue of resected HCCs was stained for CD20, CD79a and immunoglobulins and analysed for the respective cell numbers separately for tumor, infiltrative margin and distant liver stroma. These findings were correlated with clinical data and patient outcome.

CONCLUSIONS: Infiltration of HCCs by B cells is associated with prolonged patient survival. Further, a distinct B-cell like immunoglobulin profile of HCCs was identified that goes along with better patient outcome. We suggest that B cells contribute to local tumor control by secreting increased levels of immunoglobulins with antitumor activity.

Keywords: B cell; gene expression; immune infiltrate; immunoglobulin; tumor microenvironment

Conflict of interest statement

CONFLICTS OF INTEREST The authors disclose no conflicts of interest

References

  1. Clin Cancer Res. 2013 Nov 1;19(21):5994-6005 - PubMed
  2. Oncotarget. 2016 Apr 19;7(16):21853-64 - PubMed
  3. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):345-53 - PubMed
  4. PLoS One. 2013 Jul 09;8(7):e68193 - PubMed
  5. J Hepatol. 2006 Dec;45(6):868-78 - PubMed
  6. J Mol Diagn. 2003 May;5(2):73-81 - PubMed
  7. Eur J Immunol. 2015 Apr;45(4):999-1009 - PubMed
  8. World J Gastroenterol. 2013 Jan 7;19(1):8-11 - PubMed
  9. J Immunol. 2009 Sep 1;183(5):3195-203 - PubMed
  10. Cancer Res. 2010 Dec 15;70(24):10202-12 - PubMed
  11. Gut. 2017 Feb;66(2):342-351 - PubMed
  12. Anticancer Res. 2014 Apr;34(4):1563-71 - PubMed
  13. Oncoimmunology. 2015 Jun 5;5(1):e1057387 - PubMed
  14. J Proteomics. 2015 Feb 26;116:24-33 - PubMed
  15. PLoS One. 2013 Oct 16;8(10 ):e76115 - PubMed
  16. Hepatology. 2015 Dec;62(6):1779-90 - PubMed
  17. Clin Cancer Res. 2012 Jun 15;18(12):3281-92 - PubMed
  18. Hepatology. 2015 Jun;61(6):1957-67 - PubMed
  19. Int Immunopharmacol. 2014 Oct;22(2):392-9 - PubMed
  20. J Immunol. 1995 Jan 1;154(1):97-105 - PubMed
  21. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  22. PLoS One. 2014 Oct 10;9(10):e110064 - PubMed
  23. Cancer Lett. 2014 Dec 28;355(2):264-72 - PubMed
  24. Bioinformatics. 2015 Jan 15;31(2):216-24 - PubMed
  25. Ann Epidemiol. 2014 Feb;24(2):104-10 - PubMed
  26. J Gastroenterol Hepatol. 2014 Apr;29(4):851-9 - PubMed
  27. Int J Clin Exp Med. 2014 Nov 15;7(11):4282-90 - PubMed

Publication Types